Exelixis, Inc. (EXEL)
69.00
-0.84
(-1.20%)
USD |
NASDAQ |
Nov 13, 10:06
Exelixis Gross Profit Margin (Quarterly) : 96.02% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.02% |
| June 30, 2026 | 96.71% |
| March 31, 2026 | 96.73% |
| December 31, 2025 | 95.58% |
| September 30, 2025 | 96.89% |
| June 30, 2025 | 96.57% |
| March 31, 2025 | 96.55% |
| December 31, 2024 | 96.48% |
| September 30, 2024 | 96.79% |
| June 30, 2024 | 97.23% |
| March 31, 2024 | 95.00% |
| December 31, 2023 | 95.46% |
| September 30, 2023 | 96.02% |
| June 30, 2023 | 96.23% |
| March 31, 2023 | 96.50% |
| December 31, 2022 | 96.24% |
| September 30, 2022 | 96.28% |
| June 30, 2022 | 96.79% |
| March 31, 2022 | 96.29% |
| December 31, 2021 | 97.14% |
| September 30, 2021 | 96.38% |
| June 30, 2021 | 96.14% |
| March 31, 2021 | 95.12% |
| December 31, 2020 | 96.65% |
| September 30, 2020 | 96.22% |
| Date | Value |
|---|---|
| June 30, 2020 | 96.45% |
| March 31, 2020 | 95.91% |
| December 31, 2019 | 95.62% |
| September 30, 2019 | 97.23% |
| June 30, 2019 | 96.86% |
| March 31, 2019 | 96.52% |
| December 31, 2018 | 96.78% |
| September 30, 2018 | 96.73% |
| June 30, 2018 | 96.78% |
| March 31, 2018 | 97.34% |
| December 31, 2017 | 96.51% |
| September 30, 2017 | 96.95% |
| June 30, 2017 | 96.96% |
| March 31, 2017 | 96.04% |
| December 31, 2016 | 97.61% |
| September 30, 2016 | 96.05% |
| June 30, 2016 | 95.70% |
| March 31, 2016 | 95.56% |
| December 31, 2015 | 89.71% |
| September 30, 2015 | 81.74% |
| June 30, 2015 | 86.57% |
| March 31, 2015 | 88.68% |
| December 31, 2014 | 90.70% |
| September 30, 2014 | 60.36% |
| June 30, 2014 | 83.66% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 70.24% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Cytokinetics, Inc. | 87.67% |
| Gilead Sciences, Inc. | 81.09% |
| Ionis Pharmaceuticals, Inc. | 95.39% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 44.54% |
| Return on Assets | 33.26% |
| Return on Invested Capital | 40.94% |
| Profit Margin (Quarterly) | 33.11% |
| Operating Margin (Quarterly) | 40.75% |
| Return on Net Operating Assets | 165.9% |